Crombez Eric 4

What Happened

• Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical (RARE), sold 344 shares on May 5, 2026 at $24.96 per share for total proceeds of approximately $8,586.
• The Form 4 lists the transaction as a sale (S). Footnote F1 states the shares were sold to pay required tax withholdings related to the vesting of restricted stock units (RSUs), indicating a routine withholding sale rather than an independent investment decision.

Key Details

• Transaction date and price: May 5, 2026 — 344 shares at $24.96 each.
• Total proceeds: about $8,586.
• Transaction type: Sale (open market or private sale per filing).
• Footnotes:
  • F1: Sale to satisfy tax withholding on vested RSUs.
  • F2: Filing notes 558 shares were acquired under the company’s ESPP on April 30, 2026.
  • F3: References previously reported RSU awards that remain subject to vesting conditions.
• Shares owned after transaction: not specified in the excerpt provided.
• Filing timeliness: Report filed May 6, 2026 covering the May 5 transaction — appears timely; no 10b5-1 plan or late filing noted in the provided details.

Context

• Sales to cover tax withholding on vested RSUs are common and generally considered routine administrative transactions rather than directional bets on the stock.
• The dollar amount here is relatively small, so this single sale should be interpreted cautiously and in the context of other insider activity and company news.